Apr 20 (Reuters) – Johnson & Johnson, whose COVID-19 vaccine was paused last week to review reports of unusual blood clots, reported $ 100 million in first-quarter sales of the dose on Tuesday and adjusted its forecast. of benefits for the year.
The company had previously said that the vaccine would be available on a no-cost basis until the end of the pandemic.
J&J now expects a full-year adjusted profit of between $ 9.42 and 9.57 per share from its previous estimate of $ 9.40-9.60, after sales of its cancer drugs helped that quarterly earnings were up nearly 7%.
Net earnings rose to $ 6.2 billion, or $ 2.32 per share, in the first quarter, from $ 5.8 billion, or $ 2.17 per share, a year earlier.
Use of the signature COVID-19 vaccine was paused last week by US regulators as they review reports of unusual but serious blood clots in some recipients.
(Report by Manas Mishra and Manojna Maddipatla in Bengaluru; edited in Spanish by Carlos Serrano)